Paola Maycotte

Dr. Paola Maycotte

Instituto Mexicano del Seguro Social, Ciudad de Atlixco, Puebla, Mexico
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2021 in Autophagy
Verified
Journal Article
Closed access
DKDaniel J. Klionsky
Daniel J. Klionsky
AAAmal Kamal Abdel-Aziz
Amal Kamal Abdel-Aziz
SASara Abdelfatah
Sara Abdelfatah
MAMahmoud Abdellatif
Mahmoud Abdellatif
AAAsghar Abdoli
Asghar Abdoli
CTChun-Kit Tong
Chun-Kit Tong

1 February 2012 in Autophagy
Verified
Journal Article
Closed access
Paola MaycottePaola Maycotte
Paola Maycotte
SASuraj Aryal
Suraj Aryal
CCChristopher T. Cummings
Christopher T. Cummings
JTJacqueline Thorburn
Jacqueline Thorburn
MMMichael J Morgan
Michael J Morgan
ATAndrew Thorburn
Andrew Thorburn
Chloroquine (CQ) is a 4-aminoquinoline drug used for the treatment of diverse diseases. It inhibits lysosomal acidification and therefore prevents autophagy by blocking autophagosome fusion and deg...

1 November 2021 in Life Sciences
Verified
Journal Article
Closed access
FSFabiola Lilí Sarmiento-Salinas
Fabiola Lilí Sarmiento-Salinas
APAndrea Perez-Gonzalez
Andrea Perez-Gonzalez
AAAdilene Acosta-Casique
Adilene Acosta-Casique
AIAdrián Ix-Ballote
Adrián Ix-Ballote
ADAlfonso Diaz
Alfonso Diaz
Paola MaycottePaola Maycotte
Paola Maycotte

1 April 2015 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
Paola MaycottePaola Maycotte
Paola Maycotte
KJKenneth L. Jones
Kenneth L. Jones
MGMegan L. Goodall
Megan L. Goodall
JTJacqueline Thorburn
Jacqueline Thorburn
ATAndrew Thorburn
Andrew Thorburn
Autophagy is a mechanism by which cells degrade cellular material to provide nutrients and energy for survival during stress. The autophagy is thought to be a critical process for cancer stem cell (CSC) or tumor-initiating cell maintenance but the mechanisms by which autophagy supports survival of CSCs remain poorly understood. In this study, inhibition of autophagy by knockdown of ATG7 or BECN1 modified the CD44+/CD24low/− population in breast cancer cells by regulating CD24 and IL6 secretion. In a breast cancer cell line that is independent of autophagy for survival, autophagy inhibition increased IL6 secretion to the media. On the other hand, in an autophagy-dependent cell line, autophagy inhibition decreased IL6 secretion, cell survival, and mammosphere formation. In these cells, IL6 treatment or conditioned media from autophagy-competent cells rescued the deficiency in mammosphere formation induced by autophagy inhibition. These results reveal that autophagy regulates breast CSC maintenance in autophagy-dependent breast cancer cells by modulating IL6 secretion implicating autophagy as a potential therapeutic target in breast cancer. Implications: Modulation of autophagy in breast cancer has different and even opposite effects, indicating the need for a selection strategy when trying to manipulate autophagy in the context of cancer therapy. Mol Cancer Res; 13(4); 651–8. ©2015 AACR.

30 April 2014 in Cancer Research
Verified
Journal Article
Closed access
PDF file
Paola MaycottePaola Maycotte
Paola Maycotte
CGChristy M. Gearheart
Christy M. Gearheart
RBRebecca Barnard
Rebecca Barnard
SASuraj Aryal
Suraj Aryal
JLJean M. Mulcahy Levy
Jean M. Mulcahy Levy
ATAndrew Thorburn
Andrew Thorburn
Autophagy is a protein and organelle degradation pathway that is involved in diverse diseases, including cancer. Recent evidence suggests that autophagy is a cell survival mechanism in tumor cells and that its inhibition, especially in combination with other therapy, could be beneficial but it remains unclear if all cancer cells behave the same way when autophagy is inhibited. We inhibited autophagy in a panel of breast cancer cell lines and found that some of them are dependent on autophagy for survival even in nutrient rich conditions without any additional stress, whereas others need autophagy only when stressed. Survival under unstressed conditions is due to cell type–specific autophagy regulation of STAT3 activity and this phenotype is enriched in triple-negative cell lines. This autophagy-dependency affects response to therapy because autophagy inhibition reduced tumor growth in vivo in autophagy-dependent but not in autophagy-independent breast tumors, whereas combination treatment with autophagy inhibitors and other agent was preferentially synergistic in autophagy-dependent cells. These results imply that autophagy-dependence represents a tumor cell–specific characteristic where autophagy inhibition will be more effective. Moreover, our results suggest that autophagy inhibition might be a potential therapeutic strategy for triple-negative breast cancers, which currently lack an effective targeted treatment. Cancer Res; 74(9); 2579–90. ©2014 AACR.

7 June 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
FSFabiola Lilí Sarmiento-Salinas
Fabiola Lilí Sarmiento-Salinas
ADAlam Delgado-Magallón
Alam Delgado-Magallón
JMJosé Benito Montes-Alvarado
José Benito Montes-Alvarado
DRDALIA RAMIREZ
DALIA RAMIREZ
JFJuan Carlos Flores-Alonso
Juan Carlos Flores-Alonso
Paola MaycottePaola Maycotte
Paola Maycotte
Due to their crucial role in cell metabolism and homeostasis, alterations in mitochondrial biology and function have been related to the progression of diverse diseases including cancer. One of the consequences associated to mitochondrial dysfunction is the production of reactive oxygen species (ROS). ROS are known to have a controversial role during cancer initiation and progression and although several studies have tried to manipulate intracellular ROS levels using antioxidants or pro-oxidation conditions, it is not yet clear how to target oxidation for cancer therapy. In this study, we found differences in mitochondrial morphology in breast cancer cells when compared to a non-tumorigenic cell line and differences in mitochondrial function among breast cancer subtypes when exploring gene-expression data from the TCGA tumor dataset. Interestingly, we found increased ROS levels in triple negative breast cancer (TNBC) cell lines and a dependency on ROS for survival since antioxidant treatment induced cell death in TNBC cells but not in an estrogen receptor positive (ER+) cell line. Moreover, we identified the mitochondria as the main source of ROS in TNBC cell lines. Our results indicate a potential use for ROS as a target for therapy in the TNBC subtype which currently has the worst prognosis among all breast cancers and remains as the only breast cancer subtype which lacks a targeted therapy.